Developers pursuing new strategies to improve trial efficiency: Tufts CSDD

By Alexandria Pesic

- Last updated on GMT

Related tags: Pharmacology

Drug developers are pursuing new strategies to help improve the operational efficiency of their clinical trials, according to a panel of industry leaders recently convened by the Tufts Centre for the Study of Drug Development (CSDD) in Boston, US.

The panel, whose members were drawn exclusively from research-based companies, said they had begun collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, in an attempt to streamline the trial process.

“The pharmaceutical and biotech industry is facing a crisis in that it needs to develop new drugs more quickly and control expenses,” ​said Tufts CSDD senior research fellow, Ken Getz.

“Developers understand that substantial operational improvements will more likely flow from new approaches that increase the probability of success, rather than from actions which merely seek to reduce or prevent failures.”

Site failure

According to Tufts CSDD, more than two-thirds of trial sites fail to meet their patient enrolment targets. And, whereas in 2001 nearly half of all screened patients completed trials, in 2010 that figure plummeted to less than one in four.

Getz says some of the blame may lie in the ever increasing number of procedures patients are subjected to, with the median number per trial sky rocketing by 49 per cent between 2000-03 and 2004-07.

“Improving patient enrolment and controlling the number of procedures could provide substantial benefits,” ​he said.

Sponsor communication

The industry leaders convened by Tufts also agreed that communication between sponsors and investigative sites – before, during and after trials – remains critical to the development of good relations.

In addition, medical advisors to help sites better understand trial goals, testing protocols with patients prior to trials, and using electronic medical records to help define and manage data flow, were all agreed by the panel to be of paramount importance to a trial’s success.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Related suppliers

Follow us

Products

View more

Webinars